Wednesday, December 02, 2020 8:04:42 PM
In response to makindatcash.. why two new subs ... well it has to do with Legal so Charles knows why and I would imagine it is in his background of Patent Law and Intellectual Property Protection .. he is smarter than us.
But it is going through Enzolytics ENZC " THE COMPANY"
--
Formation of Two New Wholly-Owned Subsidiaries
Pursuant to the terms of the Business Combination Agreement, on November 24, 2020, the
Company [/b]formed two new Texas corporations as wholly-owned subsidiaries for the purpose of
licensing certain patented technologies: Biogenysis, Inc. and Virogentics, Inc.
Two Patent License Agreements
-
On November 30, 2020, Biogenysis, Inc., a wholly-owned subsidiary of Enzolytics, Inc., entered
into a Patent License Agreement with Bioclonetics in order to license the U.S. Provisional Patent
Application No. 63/078,482, filed September 15, 2020, entitled NOVEL HIV-BINDING
PEPTIDES for treating, preventing and reducing the risks of HIV, including all patents issuing
therefrom and any foreign counterparts thereof.
-
Also on November 30, 2020, Virogentics, Inc., a wholly-owned subsidiary of Enzolytics, Inc.,
entered into a Patent License Agreement with the Zhabilov Trust in order to license the U.S. Patent
No. 7,479538, entitled Irreversibly - Inactivated pepsinogen fragment and Pharmaceutical
composition the same for detecting preventing and treating HIV; U.S. Patent No. 8,066982,
Irreversibly - Inactivated pepsinogen fragment and Pharmaceutical composition compressing the
same for detecting preventing and treating HIV, including all patents issuing therefrom and any
foreign counterparts thereof.
But it is going through Enzolytics ENZC " THE COMPANY"
--
Formation of Two New Wholly-Owned Subsidiaries
Pursuant to the terms of the Business Combination Agreement, on November 24, 2020, the
Company [/b]formed two new Texas corporations as wholly-owned subsidiaries for the purpose of
licensing certain patented technologies: Biogenysis, Inc. and Virogentics, Inc.
Two Patent License Agreements
-
On November 30, 2020, Biogenysis, Inc., a wholly-owned subsidiary of Enzolytics, Inc., entered
into a Patent License Agreement with Bioclonetics in order to license the U.S. Provisional Patent
Application No. 63/078,482, filed September 15, 2020, entitled NOVEL HIV-BINDING
PEPTIDES for treating, preventing and reducing the risks of HIV, including all patents issuing
therefrom and any foreign counterparts thereof.
-
Also on November 30, 2020, Virogentics, Inc., a wholly-owned subsidiary of Enzolytics, Inc.,
entered into a Patent License Agreement with the Zhabilov Trust in order to license the U.S. Patent
No. 7,479538, entitled Irreversibly - Inactivated pepsinogen fragment and Pharmaceutical
composition the same for detecting preventing and treating HIV; U.S. Patent No. 8,066982,
Irreversibly - Inactivated pepsinogen fragment and Pharmaceutical composition compressing the
same for detecting preventing and treating HIV, including all patents issuing therefrom and any
foreign counterparts thereof.
TIME is an ILLUSION
---
TIMING is an actual ART
